fosamprenavir has been researched along with rosiglitazone in 1 studies
Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
---|---|---|---|---|---|
174 | 55 | 37 | 4,749 | 556 | 1,818 |
Protein | Taxonomy | fosamprenavir (IC50) | rosiglitazone (IC50) |
---|---|---|---|
CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
Bile salt export pump | Homo sapiens (human) | 4.5853 | |
Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fosamprenavir and rosiglitazone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |